financetom
Business
financetom
/
Business
/
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says
May 5, 2026 8:30 AM

11:13 AM EDT, 05/05/2026 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) is entering a "transition year" in 2026, prioritizing growth acceleration and market share gains as its expanded enzyme portfolio scales following the acquisition of Amicus Therapeutics (FOLD), Morgan Stanley said in a report Tuesday.

In its Q1 results, BioMarin raised its fiscal 2026 revenue guidance to $3.825 billion to $3.925 billion, driven by contributions from newly added therapies Galafold and Pombiliti plus Opfolda, but lowered its non-GAAP earnings per share outlook to $4.85 to $5.05 due to integration-related costs and higher interest expenses, associated with the transaction, the report said.

BioMarin is focused on scaling its expanded enzyme portfolio and driving commercial execution, with its management expected to outline a detailed roadmap in Q2 covering "long-term revenue potential," peak sales and cost synergies, the investment bank said.

Earnings are expected to be weighted toward the second half of 2026, with the Amicus deal seen by the management as "slightly dilutive" this year but "accretive" within 12 months and more meaningful in start of 2027, the report said.

The "combined enzyme portfolio" is expected to support durable growth and help offset rising competition for Voxzogo, while pipeline developments and new launches, including Palynziq expansion and BMN-333, could further support long-term growth, according to the report.

Morgan Stanley has an overweight rating on BioMarin Pharmaceutical ( BMRN ) and lowered its price target to $119 from $120.

Price: 54.26, Change: -1.20, Percent Change: -2.16

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AKCG - Public Relations Counselors Acquires Cleveland-based Hennes Communications
AKCG - Public Relations Counselors Acquires Cleveland-based Hennes Communications
May 5, 2026
The acquisition, bringing together two long-established national crisis communications agencies, strengthens AKCG's reputation management footprint GLASSBORO, N.J., May 5, 2026 /PRNewswire/ -- AKCG – Public Relations Counselors, headquartered in the Greater Philadelphia Region, today announced that it has acquired Hennes Communications, a nationally recognized crisis communications agency founded by Bruce Hennes in 1989. AKCG, which serves clients nationwide, further expands...
Alphabet closes in on Nvidia's spot as world's biggest company
Alphabet closes in on Nvidia's spot as world's biggest company
May 5, 2026
May 5 (Reuters) - Alphabet is on the cusp of overtaking Nvidia ( NVDA ) as the world's most valuable company, riding on a record stock rally fueled by its artificial intelligence efforts and booming cloud business. The potential reshuffling would put the Google parent at the No.1 spot for the first time in more than a decade. It last...
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says
May 5, 2026
11:13 AM EDT, 05/05/2026 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) is entering a transition year in 2026, prioritizing growth acceleration and market share gains as its expanded enzyme portfolio scales following the acquisition of Amicus Therapeutics (FOLD), Morgan Stanley said in a report Tuesday. In its Q1 results, BioMarin raised its fiscal 2026 revenue guidance to $3.825 billion...
Primo Brands' Q1 Faces Pressure From Service Disruptions, Cost Headwinds, RBC Says
Primo Brands' Q1 Faces Pressure From Service Disruptions, Cost Headwinds, RBC Says
May 5, 2026
11:13 AM EDT, 05/05/2026 (MT Newswires) -- Primo Brands ( PRMB ) is expected to face pressure in Q1 from extended service disruptions tied to winter storms and higher input costs linked to the Middle East conflict, RBC Capital Markets said in a note emailed Tuesday. The firm said Q1 is likely to be the weakest quarter of the year...
Copyright 2023-2026 - www.financetom.com All Rights Reserved